Coronary
Techniques and Lesion Subsets Learning Series
Pharmacotherapy
Advertisement
Episodes
Where Do Antithrombotics Fit In?
13 min.
Beyond LDL
14 min.
Expanding Your Lane and Not Your Waist: Cardiologists and GLP1-RA/SGLT2i
12 min.
Lipoprotein(a): Why Measure and What to Do?
11 min.
Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid
13 min.
Pharmacology for STEMI PCI: Which Therapies Before, Options During the Case, and Management Post
13 min.
STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors
16 min.
Antithrombotic Therapy in ACS/PCI: Case Continuation and In Hospital Management
4 min.
Unfractionated Heparin Still Works for Primary PCI!
11 min.
Cangrelor Reduces Procedural Complications and Should Be the Default Strategy
9 min.
I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors
10 min.
Longer Term DAPT Is What The Guidelines and Data Support
7 min.
The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient
7 min.
Antithrombotic Therapy in ACS/PCI: Case Resolution and Long-term Therapy
8 min.
Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI
8 min.
Case Presentation: Antithrombotic Therapy in ACS/PCI
3 min.
The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration
18 min.
Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial
18 min.
Antiplatelet Agents for Patients Undergoing PCI: Options and Pharmacologic Considerations
17 min.
Long Term Maintenance Antiplatelet Therapy After PCI
15 min.
Dual Antiplatelet Therapy After PCI: Considerations for Duration and Choice Of Drug(s)
12 min.
De-Escalation of Antithrombotic Therapy: Why, in Whom, and How?
19 min.
Standardizing the Language Around DAPT Post PCI: A Report From ARC With a Case Example
10 min.
How to Treat Microvascular Dysfunction
14 min.
What’s Next in Antithrombotic Therapy?
16 min.
Aspirin or Clopidogrel for Chronic Management?
12 min.
DAPT After PCI: Do We Need It at All?
8 min.
DAPT Duration: Unsettled or Case Closed?
13 min.
Guided Antiplatelet Therapy: Why, and in Whom?
11 min.
Standardizing The Language Around DAPT: An ARC Initiative
12 min.
A Typical PCI Case in 2023 with Longitudinal Follow Up
5 min.
For Most Patients, Only Spontaneous MI Is Relevant
6 min.
The Importance of Addressing Lipids in Patients With Complex PCI
8 min.
Novel Approaches to Reduce and Reverse Bleeding in Complex PCI
8 min.
Periprocedural MI Matters to All Patients!
4 min.
Does It Matter What Stent I Use in a HBR Patient?
8 min.
New and Emerging Pharmacology for ACS: Lipid Modulation and Anti-Inflammatory Agents
8 min.
New and Emerging Pharmacology for ACS: Factor XI Inhibition
6 min.
My Roadmap for Preprocedure and Intraprocedural Antithrombotic Therapy in Complex PCI
8 min.
PCI in Patients With AF: The Risk and Benefit of Antithrombotic Therapy
7 min.
Short DAPT or De-Escalation After ACS
7 min.
P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?
7 min.
Does Bleeding Risk Outweigh Thrombotic Risk or Vice Versa?
8 min.